Savara Inc (SVRA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -143.63M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-143.63M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-134.10M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-123.55M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $-121.30M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-117.41M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-109.16M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-103.20M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-89.65M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-81.34M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-70.37M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-60.01M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-53.25M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-45.74M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-42.91M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-38.84M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-38.60M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-38.04M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-39.11M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-41.48M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-43.85M | $1.00K | (m) | (m) | (m) | -4385000.00% |
| 2021-06-30 | $-44.66M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-43.47M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-49.30M | $257.00K | (m) | (m) | (m) | -19182.88% |
| 2020-09-30 | $-67.80M | $256.00K | (m) | (m) | (m) | -26483.20% |
| 2020-06-30 | $-69.45M | $0.00 | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-82.34M | $0.00 | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-79.03M | $0.00 | (m) | (m) | (m) | (m) |
| 2019-09-30 | $-60.76M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-61.11M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $-50.86M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-70.05M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $-66.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-59.75M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-57.29M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-29.96M | $0.00 | (m) | (m) | (m) | (m) |
| 2017-09-30 | $-50.31M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $-47.00M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $-31.41M | $222.00K | (m) | (m) | $8.09M | -14149.10% |
| 2016-12-31 | $-36.46M | $128.00K | (m) | (m) | $9.34M | -28481.25% |
| 2016-09-30 | $-37.91M | $45.00K | (m) | (m) | $9.92M | -84233.33% |
| 2016-06-30 | $-40.53M | $0.00 | (m) | (m) | $10.25M | (m) |
| 2016-03-31 | $-40.49M | $0.00 | (m) | (m) | $10.22M | (m) |
| 2015-12-31 | $-39.37M | $0.00 | (m) | (m) | $10.96M | (m) |
| 2015-09-30 | $-37.01M | $0.00 | (m) | (m) | $10.85M | (m) |
| 2015-06-30 | $-35.07M | $0.00 | (m) | (m) | $10.84M | (m) |
| 2015-03-31 | $-32.09M | $0.00 | (m) | (m) | $10.80M | (m) |
| 2014-12-31 | $-29.28M | $0.00 | (m) | (m) | $9.49M | (m) |
| 2014-09-30 | $-27.65M | (m) | (m) | (m) | $9.24M | (m) |
| 2014-06-30 | $-25.03M | (m) | (m) | (m) | $8.94M | (m) |
| 2014-03-31 | $-22.79M | (m) | (m) | (m) | $8.67M | (m) |
| 2013-12-31 | $-21.54M | (m) | (m) | (m) | $8.52M | (m) |
| 2013-09-30 | $-19.83M | (m) | (m) | (m) | $8.16M | (m) |
| 2013-06-30 | $-17.78M | (m) | (m) | (m) | $7.82M | (m) |
| 2013-03-31 | $-17.05M | (m) | (m) | (m) | $7.59M | (m) |
| 2012-12-31 | $-15.63M | $0.00 | (m) | (m) | $7.52M | (m) |
| 2012-09-30 | $-14.05M | (m) | (m) | (m) | $7.54M | (m) |
| 2012-06-30 | $-14.39M | (m) | (m) | (m) | $7.71M | (m) |
| 2012-03-31 | $-14.57M | (m) | (m) | (m) | $7.66M | (m) |
| 2011-12-31 | $-13.40M | (m) | (m) | (m) | $7.19M | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-8.54M | $488.96K | (m) | (m) | $4.99M | -1746.51% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |